Strikingly, there are several commercially available drugs that target c-Abl, which, if effective in CLN3 loss-of-function, might constitute a therapeutic approach for Batten disease, which is currently incurable. This evidence concerns the gene CLN3 and juvenile neuronal ceroid lipofuscinosis.